At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 30 enrolled
Drug / intervention
Travoprost 0.004% (Travatan) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Twelve-Week, Double Masked, Parallel Group, Primary-Therapy Pilot Study of the Safety and Efficacy of Travoprost 0.004% Compared to Pilocarpine 1% in Patients With Chronic Angle-Closure Glaucoma
In Brief
A Phase 4 clinical trial evaluating Travoprost 0.004% (Travatan) and Pilocarpine 1% for Angle-closure Glaucoma. Completed, enrolled 30 participants.
Detailed Summary
The purpose of this study is to demonstrate that the Intraocular Pressure (IOP) lowering efficacy of Travoprost Ophthalmic Solution 0.004% is superior to that of Pilocarpine 1% in patients with chronic angle-closure glaucoma (CACG).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAngle-closure Glaucoma
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2007
Primary CompletionMay 2008
First PostedSep 2008
TodayJul 2026
First PostedSep 30, 2008
Enrollment StartFeb 1, 2007
Primary CompletionMay 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 17.8 years ago
Interventions
Travoprost 0.004% (Travatan)drug
One drop in each eye, once daily at 9 AM
Pilocarpine 1%drug
One drop in each eye, forth times daily at 7 AM, 11 AM , 4 PM and 9 PM for twelve (12) weeks